Sotera Health financials
$18.60+0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $1.16B | $1.10B | $1.05B | $1.00B | $931.5M | $818.2M |
| Gross profit | $645.5M | $602.3M | $577.2M | $557.0M | $518.7M | $443.6M |
| Gross margin | 55.5% | 54.7% | 55.0% | 55.5% | 55.7% | 54.2% |
| Operating income | $362.0M | $297.6M | $276.7M | $248.3M | $256.7M | $206.0M |
| Net income | $77.9M | $44.4M | $51.4M | -$233.6M | $116.9M | -$38.6M |
| Net margin | 6.7% | 4.0% | 4.9% | −23.3% | 12.5% | −4.7% |
| Diluted EPS | $0.27 | $0.16 | $0.18 | $-0.83 | $0.41 | $-0.16 |
| EBITDA | $498.7M | $461.3M | $434.6M | $393.9M | $407.6M | $349.6M |
| Operating cash flow | $287.2M | $224.2M | -$147.7M | $278.0M | $281.5M | $120.6M |
| Free cash flow | $149.2M | $45.1M | -$362.7M | $95.6M | $179.4M | $67.1M |
| Diluted shares | 286.4M | 284.9M | 283.2M | 280.1M | 279.4M | 237.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $344.6M | $277.2M | $296.4M | $395.2M | $106.9M | $102.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $2.24B | $2.32B | $2.30B | $2.00B | $1.79B | $1.86B |
| Total assets | $3.26B | $3.07B | $3.13B | $3.12B | $2.79B | $2.76B |
| Total liabilities | $2.66B | $2.67B | $2.69B | $2.77B | $2.20B | $2.29B |
| Shareholders' equity | $606.0M | $404.9M | $443.7M | $350.2M | $586.1M | $454.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology